Clinical Scorecard: Determinants of Local Recurrence Following Stereotactic Radiation Treatment in Patients with a Single Metastasis from Breast Cancer

At a Glance

Key Highlights

• Incidence of BCBM is increasing due to improved systemic control and prolonged survival in breast cancer patients.
• Local control after craniotomy and SRT depends on radiation dose, fractionation, surgical cavity volume, tumor biology, and timing of radiation.
• Current guidelines recommend radiation to the surgical cavity post-craniotomy, favoring SRT over whole brain radiation therapy (WBRT) due to toxicity concerns and lack of overall survival benefit with WBRT.

Guideline-Based Recommendations

Diagnosis

• Confirm brain metastasis origin via pathology from surgical specimen.
• Use MRI for radiographic assessment and follow-up of local and distant intracranial failure.
• Assess breast cancer molecular subtype based on receptor status (ER, PR, HER2) for prognostic and treatment considerations.

Management

• Perform craniotomy for single brain metastasis followed by postoperative stereotactic radiation treatment (SRT) to the surgical cavity.
• Avoid surgery alone due to high local failure rates (~70% within one year).
• Prefer SRT over WBRT postoperatively to reduce toxicity without compromising overall survival.
• Determine radiation dose and fractionation based on tumor biology, cavity volume, and clinical factors.
• Incorporate systemic therapy as indicated, including endocrine therapy for ER-positive and anti-HER2 therapy for HER2-positive tumors.

Monitoring & Follow-up

• Regular MRI surveillance post-SRT to detect local recurrence and distant intracranial failure.
• Evaluate toxicity using CTCAE v5.0 criteria during follow-up.
• Monitor receptor status changes between primary tumor and brain metastasis to guide systemic therapy.

Risks

• High local failure risk with surgery alone without adjuvant radiation.
• Potential toxicity associated with WBRT leading to preference for SRT.
• Variability in local control related to breast cancer molecular subtype and radiation dosing.

Patient & Prescribing Data

62 patients with single BCBM treated with craniotomy and postoperative SRT between 2010–2022, median age 53.5 years, majority with DS-GPA 2.5–4.

HER2-positive subtype was most common (40.3%), followed by triple negative (29%), luminal B (22.5%), and luminal A (8%). Local control influenced by dose/fractionation and tumor biology; systemic therapy timing and receptor status changes impact management.

Clinical Best Practices

• Multidisciplinary tumor board discussion to individualize postoperative radiation decisions.
• Use of stereotactic radiation to the surgical cavity rather than WBRT to balance local control and toxicity.
• Consider breast cancer molecular subtype and receptor status when planning radiation dose and systemic therapy.
• Close radiographic follow-up with MRI to detect local and distant intracranial failures early.
• Incorporate systemic therapies aligned with receptor status to optimize overall disease control.

References

• Sperduto et al., Prognosis and local therapy trends in BCBM
• Society of Neuro-Oncology and International SRT guidelines
• Grubb et al., Breast cancer molecular subtype and local control with SRT
• European Society for Radiotherapy and Oncology (ESTRO) and EORTC classification